Cure8 research brief
Why This Matters
This study evaluates a less invasive endoscopic option (needle-knife stricturotomy) for Crohn’s-related anorectal strictures and reports real-world outcomes and factors linked to recurrence — information that can inform treatment discussions and expectations.
Who Should Pay Attention
Adults with Crohn’s disease and anorectal strictures, patients considering endoscopic treatment instead of surgery, clinicians who perform IBD-related endoscopy, and researchers studying stricture therapies.
Study Snapshot
What To Know
This prospective single-center cohort study evaluated endoscopic needle-knife stricturotomy (NKSt) for primary high-grade anorectal strictures in Crohn’s disease, with median follow-up about 24 months.
The procedure had 100% immediate technical success and about 70% of patients reported symptomatic improvement at 3 months; recurrence requiring re-intervention occurred in 37% of patients during follow-up.
Multivariable analysis in the report identified longer stricture length and presence of an ostomy as factors associated with higher recurrence risk, while concurrent biologic therapy was associated with lower recurrence. The authors also observed a lower recurrence rate when NKSt was combined with bleomycin injection in univariable analysis.
The paper concludes NKSt appears effective and safe but that recurrence is common and that findings need validation in larger multicenter studies.
If you are considering NKSt, these results suggest short-term symptom benefit is common but recurrence remains a significant possibility, and features such as stricture length and ostomy status may influence outcomes.
Discuss with your specialist how local experience, concurrent medical therapy (including biologics), and adjunctive techniques like injection might affect expected results.
Keep In Mind
Structured content depth: abstract — the curation is based on the article abstract provided by the journal record. The study is a single-center prospective cohort with 54 patients; authors note the need for validation in larger, multicenter trials. This is not a guideline and does not replace individualized medical advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.